DISCLAIMER: GoldInvestors.news is not a registered investment, legal or tax advisor or broker/dealer. All investment/financial opinions expressed by GoldInvestors.news are from the personal research and experience of the owner of the site and are intended as educational material. Although best efforts are made to ensure that all information is accurate and up to date, occasionally unintended errors and misprints may occur.

Pfizer delivered third quarter results that surpassed Wall Street estimates and raised its full year outlook as demand strengthened for recently launched and acquired products. The pharmaceutical company cited its “strong year-to-date performance” and continued cost cutting as drivers behind the improved guidance.

The company now expects full year revenue between $62 billion and $64 billion. Its previous forecast called for revenue of $60.5 billion to $62.5 billion, marking a meaningful increase at both ends of the projected range.

The bottom of the new sales range would be roughly flat or slightly below Pfizer’s 2025 revenue of $62.6 billion. The guidance reflects an effort to regain momentum as declining Covid product demand continues to weigh on the business.

Pfizer also lifted its adjusted profit forecast to between $2.95 and $3.05 per share for the full year. The company previously expected adjusted earnings of $2.80 to $3 per share.

The revised profit outlook includes a single $650 million charge recorded during the third quarter. That charge, which reduced earnings by 10 cents per share, was tied to Pfizer’s licensing and collaboration agreement with Chinese cancer drugmaker Innovent Biologics.

For the third quarter, Pfizer reported adjusted earnings of 87 cents per share, exceeding the 73 cents expected by analysts surveyed by LSEG. The adjusted result excluded certain items, including restructuring charges and expenses associated with intangible assets.

Third quarter revenue totaled $16.58 billion, beating the $15.87 billion expected by Wall Street. Revenue was relatively flat compared with the same period a year earlier, reflecting continued pressure from falling sales of Pfizer’s Covid products.

Pfizer cited an operational revenue decline of $57 million, primarily because of lower Covid revenue. Foreign exchange created an additional negative impact of $15 million, although stronger sales from several important products helped offset those headwinds.

Blood thinner Eliquis generated $2.52 billion in sales during the quarter, an increase of 25%. That performance exceeded the $2.40 billion analysts expected, according to estimates from StreetAccount.

Targeted cancer medicine Padcev posted quarterly revenue of $720 million, topping the $658 million expected by analysts. Padcev was among the products that helped Pfizer counter the continued deterioration in its once dominant Covid business.

Sales from Pfizer’s newly launched and acquired products increased 32% operationally. The group included Padcev, respiratory syncytial virus vaccine Abrysvo, pneumococcal vaccine Prevnar 20 and oral lung cancer treatment Lorbrena, along with several other products.

Even Pfizer’s declining Covid products performed better than analysts anticipated during the quarter. The company’s Covid vaccine generated $808 million in sales, ahead of StreetAccount’s estimate of $770.4 million.

Paxlovid, Pfizer’s antiviral pill, produced $449 million in quarterly sales. Analysts had expected revenue of $394.1 million, making the drug another contributor to the company’s better than expected quarter despite the broader drop in Covid demand.

Pfizer recorded net income of $3.24 billion, or 56 cents per share, for the quarter. That compared with net income of $3.54 billion, or 62 cents per share, during the third quarter of 2025.

The company is attempting a comeback after its enormous pandemic era success faded. Chief Executive Officer Albert Bourla is pursuing growth through strategic acquisitions, new cancer medicines and a major push into weight loss treatments through Pfizer’s acquisition of Metsera.

At the same time, generic competition threatens some of Pfizer’s biggest revenue producers. The company expanded its multiyear cost cutting program in August to help offset sharp declines in sales from Covid products.

Pfizer is now targeting approximately $9.7 billion in net savings through 2029. Those planned savings, combined with growth from newer medicines and acquired products, form the core of its effort to improve performance as older revenue streams weaken.

Pfizer also named company veteran Cecile Guegan as chief financial officer this month. Guegan has held multiple finance leadership positions at Pfizer over the past two decades and had served as interim CFO since August.

She succeeded Dave Denton, Pfizer’s former chief financial officer, who stepped down in August to accept the same role at Nike. Her appointment adds permanent financial leadership as Pfizer presses forward with higher guidance, cost reductions and growth from its expanded product portfolio.

DISCLAIMER: GoldInvestors.news is not a registered investment, legal or tax advisor or broker/dealer. All investment/financial opinions expressed by GoldInvestors.news are from the personal research and experience of the owner of the site and are intended as educational material. Although best efforts are made to ensure that all information is accurate and up to date, occasionally unintended errors and misprints may occur.